As costs continue to escalate for cell and gene therapies, Tokio Marine HCC – Stop Loss Group (TMHCC) has partnered with Emerging Therapy Solutions (ETS) for a best-in-class service to positively impact the plan and patient.

Abecma was approved by the FDA on March 21, 2021 to treat Refractory Multiple Myeloma in adults. Click here to read ETS’s therapy review of this new cell therapy treatment.

Read more about cost management opportunities for cell and gene therapies here, or follow the links below to learn more about other FDA approved treatments.

Please contact your regional marketing representative to learn more on how TMHCC in partnership with ETS can positively impact your clients' healthcare plans.

TMHCC has been helping protect self-funded plan sponsors from catastrophic claim events for over 45 years. Rated A++ (superior) by A.M. Best Company, AA- (very strong) by Standard & Poor’s, and AA- (very strong) by Fitch Ratings, TMHCC is a leading provider of medical stop loss coverage provided through brokers, consultants and third-party administrators. By listening to the demands of the market, we have developed exceptional products, unparalleled resources and value-added services that set us apart in the industry. Visit our website to learn more about our innovative stop loss, Taft-Hartley, captive and organ transplant solutions.

*Estimated cost ranges provided by ETS.